Sydney Kruger

Sydney Kruger has a diverse work history in the field of clinical operations. Sydney is currently the Head of Clinical Operations at Lung Therapeutics, Inc. since January 2023. Prior to this, they held the position of Senior Director of Clinical Operations at Inhibikase Therapeutics, Inc. from March 2022 to January 2023. Before that, they worked as the Director of Clinical Operations at the same company from August 2021 to March 2022.

Between 2018 and 2021, Sydney worked at Apellis Pharmaceuticals, first as an Associate Director of Clinical Operations from October 2019 to August 2021, and then as a Senior Clinical Trial Manager from March 2018 to October 2019.

Sydney also gained experience at Intarcia Therapeutics, Inc. as a Clinical Project Manager from October 2016 to March 2018. Prior to that, they worked at Premier Research as a Project Manager from April 2016 to October 2016.

Sydney's early career includes various roles at Quintiles, where they worked as a Clinical Project Manager from April 2015 to March 2016, an Associate Clinical Project Manager from April 2014 to April 2015, and a Clinical Project Support Specialist from April 2013 to April 2014.

Sydney began their career at WorldCare Clinical, initially as an Operations Intern from October 2011 to April 2012, and then as a Clinical Research Associate from May 2012 to April 2013. Throughout their roles, Sydney has demonstrated expertise in clinical protocol design, project management, data analysis, and regulatory compliance.

Sydney Kruger pursued their education in a chronological manner. Starting in 2007, they attended Northeastern University, where they obtained a Bachelor of Science degree in Health Science in 2011. Sydney furthered their education at the same institution in 2012, earning a Graduate Certificate in Health/Health Care Administration/Management. Later, in 2016, they enrolled again at Northeastern University to pursue a Master of Science degree in Leadership and Health Management, which they completed in 2017.